News

Asgard lands €2.5M EIC grant to push cancer therapy toward clinic

What's the deal? Asgard Therapeutics, a Lund, Sweden-based biotech, has been awarded a €2.5 million European Innovation Council (EIC) Accelerator grant to advance its lead program, AT-108, into clinical development. The company was one of 35 selected from 453 proposals in the EIC's latest evaluation round.

What does Asgard do? It develops in vivo direct cell reprogramming for cancer immunotherapy. AT-108 is a first-in-class, off-the-shelf treatment that reprograms tumor-resident cells into dendritic-like cDC1 cells, triggering an anti-tumor immune response.

Why now? The non-dilutive grant funds preparatory work to take AT-108 into a first-in-human trial in 2027. It follows a recent study published in Immunity and new translational biomarker data presented at SITC 2026.

What's next? The grant also makes Asgard eligible for up to €10 million in equity investment from the EIC Fund, as part of a wider financing round. That sum is not committed funding.

"This €2.5 million EIC Accelerator grant caps a fantastic year for Asgard, in which we have made huge progress on the road to becoming a clinical-stage company," said Cristiana Pires, co-founder and chief executive officer.

By the numbers: The award builds on a €30 million Series A and brings Asgard's reported funding to €36 million, backed by Novo HoldingsDealroom has a profile for this one. Try Dealroom →, Johnson & Johnson Innovation, Boehringer Ingelheim Venture FundDealroom has a profile for this one. Try Dealroom →, Industrifonden, and RV InvestDealroom has a profile for this one. Try Dealroom →.

The signal: The grant ranks among the largest for health startups in Sweden, in the 95th percentile of such rounds. It marks support for translating an unusual preclinical approach into clinical testing — not yet proof that it works in patients.

Read more: streetinsider.com

Image credit: "Life on a Grain of Sand 2" by adonofrio (Biology101.org), licensed under CC BY 2.0

More top stories